Palantir stock could climb another 20%, BofA says. The bank lifted its price target on the stock, pointing in particular to Palantir's agentic AI. The tech could help lift commercial sales past $10 billion by 2030, it predicted. Palantir's big rally might have room to run. Bank of America said it believes shares of the AI company beloved by retail traders have a lot more upside. Growth will be sustained by one secret weapon in particular: AI forward-deployed engineers, the bank said, referring to P ...

Core Insights - Velocity Clinical Research has formed a strategic partnership with Palantir Technologies to automate the payments reconciliation process in clinical trials, utilizing advanced AI technology [1][4][6] - The collaboration aims to address the fragmented and inefficient nature of invoice and payment reconciliation in clinical research, which has historically been time-consuming and error-prone [2][5] - The automated solution integrates Palantir's AI technology with Velocity's workflows, significantly reducing the time required for financial tasks and allowing finance teams to focus on higher-value activities [3][5][7] Company Overview - Velocity Clinical Research is a leading integrated site organization for clinical trials, operating over 70 sites and collaborating with more than 220 investigators [8] - The company partners with pharmaceutical and biotechnology firms to conduct research on new drugs, medical devices, and diagnostics, aiming to enhance human health and wellbeing [8] - Velocity also has a technology hub in India, where it develops innovative systems to leverage extensive site, patient, and historical performance data [9]